肺腺癌中C-met的表達與EGFR-TKIs耐藥的相關(guān)性研究
發(fā)布時間：2018-11-24 19:21
【摘要】：目的:檢測肺腺癌中C-met蛋白表達與基因擴增情況,探討二者與臨床病理特征的關(guān)系,并分析其與EGFR-TKIs耐藥和預后的關(guān)系。方法:選取120例(80例接受EGFR-TKIs治療,40例未接受EGFR-TKIs治療)肺腺癌組織。1.應用免疫組織化學EnVision方法進行TTF-1、Napsin A、CK7及C-met蛋白表達檢測。2.應用熒光原位雜交技術(shù)(FISH)進行C-met基因擴增狀態(tài)檢測。結(jié)果:1.120例肺腺癌組織中C-met蛋白高表達者21例,C-met基因擴增者13例。80例接受EGFR-TKIs治療的患者中,46例出現(xiàn)靶向耐藥,C-met蛋白高表達30.43%(14/46),C-met基因擴增19.57%(9/46),兩者均高于接受靶向治療而未出現(xiàn)耐藥表現(xiàn)患者。2.C-met蛋白高表達與年齡、病理分級、臨床分期有關(guān)(P0.05),而與性別、吸煙史、淋巴結(jié)轉(zhuǎn)移無關(guān)(P0.05)。C-met基因擴增與臨床分期有關(guān)(P0.05),而與年齡、性別、吸煙史、病理分級、淋巴結(jié)轉(zhuǎn)移無關(guān)(P0.05)。3.耐藥患者中,蛋白高表達且基因擴增者6例,統(tǒng)計分析表明,耐藥患者中C-met蛋白高表達與基因擴增二者呈正相關(guān)(rs=0.388)。而40例未接受TKIs治療患者中C-met蛋白高表達與基因擴增差異無統(tǒng)計學意義(P0.05)。4.C-met基因擴增陰性組患者3年生存率高于基因擴增陽性組,差異有統(tǒng)計學意義(P0.05);C-met蛋白低表達組患者3年生存率高于C-met蛋白高表達組,但差異無統(tǒng)計學意義(P0.05)。Cox回歸分析表明,C-met基因擴增是影響預后的獨立因素。結(jié)論:1.C-met在肺腺癌中處于高表達狀態(tài)。2.C-met蛋白高表達與年齡、病理分級、臨床分期有關(guān)。C-met基因擴增與臨床分期有關(guān)。3.接受靶向治療而出現(xiàn)耐藥表現(xiàn)的肺腺癌患者中,C-met蛋白表達與基因擴增具有相關(guān)性。4.C-met基因擴增提示預后較差,可作為預后評估的一個獨立因素。
[Abstract]:Objective: to investigate the relationship between C-met protein expression and gene amplification in lung adenocarcinoma and its relationship with clinicopathological features, drug resistance and prognosis of EGFR-TKIs. Methods: 120 cases of lung adenocarcinoma (80 cases treated with EGFR-TKIs and 40 cases not treated with EGFR-TKIs) were selected. 1. Immunohistochemical EnVision method was used to detect the expression of TTF-1,Napsin ACK7 and C-met protein. 2. The amplification status of C-met gene was detected by fluorescence in situ hybridization (FISH). Results: there were 21 cases of high expression of C-met protein and 13 cases of C-met gene amplification in 1.120 cases of lung adenocarcinoma. In 80 cases of patients treated with EGFR-TKIs, 46 cases showed targeted drug resistance, and the overexpression of C-met protein was 30.43% (14 / 46). The C-met gene amplification rate was 19.57% (9 / 46). The high expression of 2.C-met protein was correlated with age, pathological grade and clinical stage (P0.05), but with sex. C-met gene amplification was related to clinical stage (P0.05), but not to age, sex, smoking history, pathological grade, lymph node metastasis (P0.05). There were 6 cases of high protein expression and gene amplification in drug-resistant patients. Statistical analysis showed that the high expression of C-met protein was positively correlated with gene amplification (rs=0.388) in drug-resistant patients. However, there was no significant difference between the high expression of C-met protein and gene amplification in 40 patients without TKIs (P0.05). The 3-year survival rate of 4.C-met gene negative group was higher than that of gene amplification positive group. The difference was statistically significant (P0.05). The 3-year survival rate of patients with low expression of C-met protein was higher than that of patients with high expression of C-met protein, but the difference was not statistically significant (P0.05). Cox regression analysis showed that C-met gene amplification was an independent factor affecting prognosis. Conclusion: the expression of 1.C-met is high in lung adenocarcinoma. The high expression of 2.C-met protein is related to age, pathological grade and clinical stage. The amplification of C-met gene is related to clinical stage. The expression of C-met protein was correlated with gene amplification in lung adenocarcinoma patients with drug resistance after targeted therapy. 4.C-met gene amplification suggested poor prognosis and could be used as an independent prognostic factor.
【學位授予單位】：山西醫(yī)科大學
【學位級別】：碩士
【學位授予年份】：2017
【分類號】：R734.2
本文編號：2354746
[Abstract]:Objective: to investigate the relationship between C-met protein expression and gene amplification in lung adenocarcinoma and its relationship with clinicopathological features, drug resistance and prognosis of EGFR-TKIs. Methods: 120 cases of lung adenocarcinoma (80 cases treated with EGFR-TKIs and 40 cases not treated with EGFR-TKIs) were selected. 1. Immunohistochemical EnVision method was used to detect the expression of TTF-1,Napsin ACK7 and C-met protein. 2. The amplification status of C-met gene was detected by fluorescence in situ hybridization (FISH). Results: there were 21 cases of high expression of C-met protein and 13 cases of C-met gene amplification in 1.120 cases of lung adenocarcinoma. In 80 cases of patients treated with EGFR-TKIs, 46 cases showed targeted drug resistance, and the overexpression of C-met protein was 30.43% (14 / 46). The C-met gene amplification rate was 19.57% (9 / 46). The high expression of 2.C-met protein was correlated with age, pathological grade and clinical stage (P0.05), but with sex. C-met gene amplification was related to clinical stage (P0.05), but not to age, sex, smoking history, pathological grade, lymph node metastasis (P0.05). There were 6 cases of high protein expression and gene amplification in drug-resistant patients. Statistical analysis showed that the high expression of C-met protein was positively correlated with gene amplification (rs=0.388) in drug-resistant patients. However, there was no significant difference between the high expression of C-met protein and gene amplification in 40 patients without TKIs (P0.05). The 3-year survival rate of 4.C-met gene negative group was higher than that of gene amplification positive group. The difference was statistically significant (P0.05). The 3-year survival rate of patients with low expression of C-met protein was higher than that of patients with high expression of C-met protein, but the difference was not statistically significant (P0.05). Cox regression analysis showed that C-met gene amplification was an independent factor affecting prognosis. Conclusion: the expression of 1.C-met is high in lung adenocarcinoma. The high expression of 2.C-met protein is related to age, pathological grade and clinical stage. The amplification of C-met gene is related to clinical stage. The expression of C-met protein was correlated with gene amplification in lung adenocarcinoma patients with drug resistance after targeted therapy. 4.C-met gene amplification suggested poor prognosis and could be used as an independent prognostic factor.
【學位授予單位】：山西醫(yī)科大學
【學位級別】：碩士
【學位授予年份】：2017
【分類號】：R734.2
【參考文獻】
相關(guān)期刊論文 前10條
1 梁紅格;王孟昭;;c-MET在非小細胞肺癌中的作用機制及其治療和檢測[J];中國肺癌雜志;2015年12期
2 周韶璋;宋向群;;HGF/c-Met信號傳導通路與晚期非小細胞肺癌關(guān)系的研究進展[J];中國癌癥防治雜志;2015年05期
3 張杰;邵晉晨;朱蕾;;2015版WHO肺腫瘤分類解讀[J];中華病理學雜志;2015年09期
4 蔣濤;周彩存;;HGF/c-MET抑制劑治療非小細胞肺癌的研究進展[J];中國肺癌雜志;2015年04期
5 喬洪源;陳建新;余宗陽;歐陽學農(nóng);;HGF及其c-MET受體在非小細胞肺癌中的研究進展[J];中國腫瘤;2014年02期
6 屈晶晶;顧其華;胡成平;;C-MET在非小細胞肺癌對表皮生長因子受體酪氨酸激酶抑制劑耐藥中的作用研究進展[J];國際呼吸雜志;2012年19期
7 張楠;李恒;劉杰;劉金峰;王婧男;孫玉萍;;肝細胞生長因子及其受體c-met在非小細胞肺癌中的表達及其與淋巴管生成的關(guān)系[J];腫瘤研究與臨床;2011年08期
8 艾婷;王寧;宋麗萍;;EGFR和c-Met基因的相對拷貝數(shù)在非小細胞肺癌預后中的意義[J];南方醫(yī)科大學學報;2011年02期
9 席晨輝;范子義;莊大勇;鄭魯明;段松建;何君美;范西紅;賀青卿;;乳腺癌中HER-2蛋白表達及基因擴增檢測的比較研究[J];中華內(nèi)分泌外科雜志;2010年05期
10 艾婷;王寧;李圍圍;宋麗萍;;表皮生長因子受體和肝細胞生長因子受體在非小細胞肺癌中的表達及其與預后的關(guān)系[J];中華腫瘤雜志;2010年11期
，本文編號：2354746
本文鏈接：http://www.sikaile.net/yixuelunwen/zlx/2354746.html
最近更新
教材專著
